Study guide
3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management
Key Takeaways Explain This Topic AI
Primary dysmenorrhea is mediated by elevated endometrial prostaglandin F2-alpha (PGF2-alpha) production causing myometrial hypercontractility and ischemia, characteristically presenting with a normal physical exam.
First-line pharmacotherapy for primary dysmenorrhea consists of NSAIDs initiated 1 to 2 days prior to anticipated menses, or combined hormonal contraceptives that suppress ovulation and endometrial proliferation.
Endometriosis is characterized by ectopic endometrial glands and stroma presenting with the classic triad of secondary dysmenorrhea, deep dyspareunia, and dyschezia, along with subfertility and uterosacral nodularity.
Histologic confirmation at laparoscopy is the reference standard, but ESHRE (2022) supports diagnosis from symptoms and imaging with empiric hormonal treatment before surgery; medical suppression uses continuous hormonal contraceptives, progestins, GnRH agonists with add-back therapy, or oral GnRH antagonists.
Chronic pelvic pain (CPP) is cyclic or noncyclic pain of pelvic origin, typically lasting 6 months or longer, requiring comprehensive multidisciplinary evaluation of gynecologic, urologic, gastrointestinal, and myofascial systems.
Last updated: October 2026
Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management
Important
While empiric medical therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) or hormonal suppression should be initiated promptly upon clinical suspicion of endometriosis, diagnostic laparoscopy with histologic biopsy of peritoneal or ovarian lesions remains the definitive gold standard for confirmation. An absence of physical exam findings never rules out endometriosis.
Primary Versus Secondary Dysmenorrhea
Dysmenorrhea refers to painful, cramping pelvic discomfort associated with menstruation. Clinically, it is classified into primary or secondary etiologies:
Characteristic Primary Dysmenorrhea Secondary Dysmenorrhea
Pathophysiology Excess endometrial prostaglandin F2-alpha (PGF2-alpha) and PGE2 causing myometrial hypercontractility and ischemia Underlying organic pelvic pathology (endometriosis, adenomyosis, fibroids, PID, adhesions)
Onset 6 to 12 months after menarche, coincident with regular ovulatory cycles Begins years after menarche (often 20s to 40s); progressively worsens over time
Pain Timing Begins a few hours before or at onset of menstrual flow; peaks within 24 to 48 hours May begin days before menses, persist throughout bleeding, and extend into the intermenstrual phase
Associated Symptoms Prostaglandin-mediated symptoms: nausea, vomiting, loose stools, fatigue, headache Etiology-dependent: deep dyspareunia, dyschezia, heavy bleeding, chronic pelvic pain
Physical Examination Completely normal pelvic examination; no pelvic masses or cervical motion tenderness Frequently abnormal: enlarged or irregular uterus, uterosacral nodularity, fixed retroversion
Pathophysiology of Primary Dysmenorrhea
Progesterone withdrawal at the end of the luteal phase triggers lysosomal enzyme release, mobilizing arachidonic acid and stimulating cyclooxygenase (COX) to produce high levels of prostaglandin F2-alpha (PGF2-alpha). PGF2-alpha causes potent myometrial vasoconstriction and uncoordinated, high-pressure uterine contractions exceeding 100 to 120 mmHg (surpassing uterine arterial pressure). This induces transient myometrial ischemia, anaerobic metabolite accumulation, and activation of pelvic nociceptive fibers.
First-Line Pharmacotherapy for Primary Dysmenorrhea
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) : First-line medical therapy. NSAIDs inhibit COX-1 and COX-2 enzymes, suppressing prostaglandin synthesis. To achieve maximal efficacy, NSAIDs must be initiated 1 to 2 days prior to anticipated menses or at the earliest sign of cramping, and taken on a scheduled basis for 48 to 72 hours. First-line agents include ibuprofen (600–800 mg PO every 8 hours) or naproxen sodium (550 mg loading dose, followed by 275 mg every 6 to 8 hours).
Hormonal Contraceptives : For patients who fail NSAIDs, require contraception, or desire cycle control, combined hormonal contraceptives (pills, patch, vaginal ring) or progestin methods (52 mg levonorgestrel IUS, etonogestrel implant, DMPA) serve as first-line therapy by suppressing ovulation, reducing endometrial proliferation, and decreasing menstrual prostaglandin output.
Endometriosis: Pathogenesis, Presentation, and Staging
Endometriosis is an estrogen-dependent chronic condition defined by the presence of ectopic endometrial glands and stroma outside the uterine cavity. The primary pathogenic framework is Sampson's theory of retrograde menstruation, where sloughed menstrual tissue migrates through the fallopian tubes into the peritoneal cavity, implanting and inciting local inflammation, fibrosis, and adhesion formation.
Clinical Presentation
The hallmark presentation includes the "classic triad":
Secondary Dysmenorrhea : Severe, progressive cramping poorly responsive to standard analgesics.
Deep Dyspareunia : Sharp, deep pelvic pain during sexual penetration caused by traction on the uterosacral ligaments or the pouch of Douglas.
Dyschezia : Painful defecation, particularly during menses, reflecting rectovaginal septum involvement.
Other manifestations include subfertility (affecting 30% to 50% of patients due to anatomical distortion and peritoneal inflammatory toxicity), catamenial dysuria, and non-cyclical chronic pelvic pain.
Physical Examination Findings
Classic examination findings include:
Exquisite focal tenderness and palpable nodularity along the uterosacral ligaments .
A fixed, immobile, retroverted uterus held by fibrotic adhesions.
Firm, tender nodules in the posterior vaginal fornix (occasionally visible as bluish implants on speculum exam).
Tender, fixed adnexal fullness or mass indicative of an endometrioma ("chocolate cyst").
Diagnosis and Staging
Transvaginal ultrasound (TVUS) detects ovarian endometriomas (homogeneous, low-level, "ground-glass" internal echoes) and deep infiltrating disease, but has limited sensitivity for superficial peritoneal implants. The definitive gold standard for diagnosis is diagnostic laparoscopy with histologic biopsy confirming ectopic endometrial glands and stroma. ESHRE (2022), however, no longer requires laparoscopy before treatment: normal imaging does not exclude superficial disease, and empiric hormonal therapy is reasonable when symptoms fit.
The revised American Society for Reproductive Medicine (ASRM) classification stages disease from Stage I (minimal), Stage II (mild), Stage III (moderate), to Stage IV (severe):
Note
A critical rule for the WHNP-BC examination: ASRM anatomic staging correlates with anatomical distortion and surgical difficulty, but correlates poorly with pain severity. A patient with minimal Stage I peritoneal implants may experience disabling, severe pain, whereas an individual with Stage IV extensive adhesive disease may remain asymptomatic until evaluated for infertility.
Medical and Surgical Management of Endometriosis
Medical therapy suppresses ovarian estrogen production and induces atrophy of ectopic implants:
First-Line Medical Therapies
Continuous Combined Oral Contraceptives (COCs) : Continuous regimens without a placebo interval suppress ovulation and induce decidualization and atrophy of ectopic lesions.
High-Dose Progestins :
Norethindrone acetate : 5 mg daily, titrated up to 15 mg daily to achieve amenorrhea.
Dienogest : 2 mg daily (marketed for endometriosis outside the United States), an oral progestin with selective anti-proliferative and anti-inflammatory activity against endometriotic implants.
Levonorgestrel 52 mg IUS : Significantly reduces dysmenorrhea and pelvic pain associated with peritoneal disease.
Second-Line Medical Therapies
GnRH Agonists : Leuprolide acetate (3.75 mg monthly IM or 11.25 mg every 3 months). After a transient initial flare, continuous receptor stimulation downregulates pituitary GnRH receptors, inducing a hypoestrogenic state.
Add-Back Therapy : To prevent rapid bone mineral density (BMD) loss and severe vasomotor symptoms, mandatory add-back therapy with norethindrone acetate (5 mg daily) with or without low-dose estrogen must be co-prescribed.
Oral GnRH Antagonists : Elagolix (150 mg daily for up to 24 months, or 200 mg twice daily for up to 6 months) and relugolix combination therapy competitively bind GnRH receptors, providing dose-dependent estradiol suppression without an initial hormonal flare.
Surgical Interventions
Conservative Laparoscopy : Excision or ablation of visible implants, adhesiolysis, and ovarian cystectomy (excising the endometrioma capsule while preserving healthy ovarian cortex).
Definitive Surgery : Total hysterectomy with bilateral salpingo-oophorectomy (BSO) for completed childbearing and refractory pain.
Chronic Pelvic Pain (CPP) & Multidisciplinary Evaluation
Chronic pelvic pain (ACOG Practice Bulletin 218) is cyclic or noncyclic pain perceived to originate from pelvic organs, localized to the anatomical pelvis, anterior abdominal wall at or below the umbilicus, lower back, or buttocks, persisting for at least 6 months , and causing functional disability.
CPP frequently involves overlapping non-gynecologic organ systems:
Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) : Chronic suprapubic discomfort or bladder pressure associated with urgency and frequency, characteristically relieved by voiding.
Irritable Bowel Syndrome (IBS) : Recurrent abdominal pain associated with defecation and altered bowel habits, diagnosed using Rome IV criteria.
Myofascial Pelvic Pain : Hypertonicity and trigger points in the levator ani and obturator internus muscles. Evaluated via internal pelvic floor muscle palpation. Carnett's sign (abdominal tenderness persisting or worsening when the patient tenses abdominal muscles) differentiates abdominal wall trigger points from visceral disease.
Multidisciplinary Management : Specialized pelvic floor physical therapy (PFPT) focusing on relaxation, trigger point release, and down-training (avoiding Kegels in hypertonic floors); neuropathic agents (gabapentin, amitriptyline); and cognitive-behavioral therapy (CBT).